Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-RM26-RGD PET/CT in GRPR and αvβ3 Positive Tumors
NCT05549024Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-RM26-RGD in breast cancer, prostate cancer (PCa) and brain tumor (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Diagnostic performance 1 at 1 year, Diagnostic performance 2 at 1 year and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
68Ga-RM26-RGD
03
Conditions
breast cancerprostate cancer (PCa)brain tumor
Beyond the preview
Go deeper on NCT05549024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549024.